PFIZER INC. AND TRANSTECH PHARMA, INC. ENTER INTO $155 MILLION AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF RAGE MODULATORS

Pfizer Inc and TransTech Pharma, Inc. announced that they have entered into a license agreement for the development and commercialization of small and large molecule compounds under development by TransTech. These compounds target the receptor for advanced glycation end products (RAGE) and have potential use in the treatment of Alzheimer's disease, a progressive illness that kills nerve cells in the brain afflicting some 18 million people worldwide.

BioSpace (http://www.biospace.com/news_story.aspx?StoryID=30197&full=1)